Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.10.0.1
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Revenue from contract with customer $ 22,000   $ 287,000    
Grant and other revenue 209,146 $ 223,669 762,549 $ 1,315,298  
Revenue 231,458 223,669 1,050,030 1,415,298  
Cost of revenue 38,101 73,811  
Research and development expenses 1,225,770 874,547 3,367,444 2,765,695  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 2,651,113 1,684,381 6,141,386 8,809,070  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 37,590 50,326 113,088 197,655  
Loss from operations (3,721,116) [3] (2,385,585) (8,645,699) [3] (10,357,122) [3]  
Other expense (24,534) [4] 69,071 (4,284,014) [4] (1,061,190) [4]  
Income tax expense (76,259) 775,750 (65,330) 3,861,156  
Net loss from continuing operations (3,821,909) (1,540,764) (12,995,043) (7,557,156)  
Net income (loss) (3,821,909) (1,389,488) (12,953,928) 79,004,006  
Total assets, net of depreciation and amortization 9,109,042   9,109,042   $ 20,781,436
Capital expenditures 16,152 23,247 19,317 31,417  
Other income (24,534) [4] 69,071 (4,284,014) [4] (1,061,190) [4]  
(Loss) income from discontinued operations 5,399 (1,938) (332,838)  
Gain on sale of discontinued operations, net of tax 145,877 43,053 86,894,000  
Net loss (3,821,909) (1,389,488) (12,953,928) 79,004,006  
UNITED STATES          
Total assets, net of depreciation and amortization 9,089,645 22,521,506 9,089,645 22,521,506  
Non-US [Member]          
Total assets, net of depreciation and amortization 19,397 84,201 19,397 84,201  
Royalty [Member]          
Revenue from contract with customer 2,382 9,842  
License [Member]          
Revenue from contract with customer 19,930 277,639 100,000  
Diagnostics Segment [Member]          
Grant and other revenue 65,505 210,479 454,830 1,200,216  
Revenue 87,817   742,311 1,300,216  
Cost of revenue 38,101   73,811    
Research and development expenses 711,355 734,539 2,409,524 2,255,842  
Selling, general and administrative expenses, excluding depreciation and amortization [1]  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations (661,639) [3] (524,060) (1,741,024) [3] (955,626) [3]  
Other expense [4] [4] [4]  
Income tax expense (10,081) 175,496 (8,797) 323,149  
Net loss from continuing operations (671,720) (348,564) (1,749,821) (632,477)  
Net income (loss) (671,720) (197,288) (1,708,706) 85,928,685  
Capital expenditures  
Other income [4] [4] [4]  
(Loss) income from discontinued operations   5,399 (1,938) (332,838)  
Gain on sale of discontinued operations, net of tax   145,877 43,053 86,894,000  
Net loss (671,720) (197,288) (1,708,706) 85,928,685  
Diagnostics Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 117,722 14,675,489 117,722 14,675,489  
Diagnostics Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization 18,239 82,334 18,239 82,334  
Diagnostics Segment [Member] | Royalty [Member]          
Revenue from contract with customer 2,382   9,842    
Diagnostics Segment [Member] | License [Member]          
Revenue from contract with customer 19,930   277,639 100,000  
Therapeutics Segment [Member]          
Grant and other revenue 143,641 13,190 307,719 115,082  
Revenue 143,641   307,719 115,082  
Cost of revenue      
Research and development expenses 514,415 140,008 957,920 509,853  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 20,532 13,359 45,769 19,342  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations (391,306) [3] (140,177) (695,970) [3] (414,113) [3]  
Other expense [4] [4] [4]  
Income tax expense (3,879) 46,942 (3,517) 140,034  
Net loss from continuing operations (395,185) (93,235) (699,487) (274,079)  
Net income (loss) (395,185) (93,235) (699,487) (274,079)  
Capital expenditures  
Other income [4] [4] [4]  
(Loss) income from discontinued operations    
Gain on sale of discontinued operations, net of tax    
Net loss (395,185) (93,235) (699,487) (274,079)  
Therapeutics Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 72,622 10,591 72,622 10,591  
Therapeutics Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization  
Therapeutics Segment [Member] | Royalty [Member]          
Revenue from contract with customer      
Therapeutics Segment [Member] | License [Member]          
Revenue from contract with customer    
Corporate Segment [Member]          
Grant and other revenue  
Revenue    
Cost of revenue      
Research and development expenses  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 2,630,581 1,671,022 6,095,617 8,789,728  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 37,590 50,326 113,088 197,655  
Loss from operations (2,668,171) [3] (1,721,348) (6,208,705) [3] (8,987,383) [3]  
Other expense (24,534) [4] 69,071 (4,284,014) [4] (1,061,190) [4]  
Income tax expense (62,299) 553,312 (53,017) 3,397,972  
Net loss from continuing operations (2,755,004) (1,098,965) (10,545,736) (6,650,601)  
Net income (loss) (2,755,004) (1,098,965) (10,545,736) (6,650,601)  
Capital expenditures 16,152 23,247 19,317 31,417  
Other income (24,534) [4] 69,071 (4,284,014) [4] (1,061,190) [4]  
(Loss) income from discontinued operations    
Gain on sale of discontinued operations, net of tax    
Net loss (2,755,004) (1,098,965) (10,545,736) (6,650,601)  
Corporate Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 8,899,301 7,835,426 8,899,301 7,835,426  
Corporate Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization 1,158 $ 1,867 1,158 1,867  
Corporate Segment [Member] | Royalty [Member]          
Revenue from contract with customer      
Corporate Segment [Member] | License [Member]          
Revenue from contract with customer    
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($37,590 and $50,326 for the three-month periods ended September 30, 2018 and 2017, and $113,088 and $197,655 for the nine-month periods ended September 30, 2018 and 2017, respectively).
[3] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.